<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681447</url>
  </required_header>
  <id_info>
    <org_study_id>protocol 15</org_study_id>
    <nct_id>NCT00681447</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Low Back and Lower Extremity Pain</brief_title>
  <official_title>A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Lumbar Interlaminar Epidural Injections in Lumbar Disc Herniation, and Discogenic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pain Management Center of Paducah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pain Management Center of Paducah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To demonstrate clinically significant improvements in patients undergoing lumbar&#xD;
           interlaminar epidurals. Improvement will be assessed in relation to the clinical outcome&#xD;
           measures of pain and function.&#xD;
&#xD;
        2. To evaluate and compare the adverse event profile in all patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate clinically significant improvement or lack thereof with the lumbar interlaminar epidural patients with or without steroids.</measure>
    <time_frame>Patients will return for follow-up visits at 3, 6, 12, 18, and 24 months post-treatment. The recruitment period is estimated as 24 months with an anticipated study duration of 48 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate differences in outcomes in patients receiving steroids compared to those patients randomized to the local anesthetic group who did not receive steroids.</measure>
    <time_frame>Patients will return for follow-up visits at 3, 6, 12, 18, and 24 months post-treatment. The recruitment period is estimated as 24 months with an anticipated study duration of 48 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare the adverse event profile in all patients.</measure>
    <time_frame>Patients will return for follow-up visits at 3, 6, 12, 18, and 24 months post-treatment. The recruitment period is estimated as 24 months with an anticipated study duration of 48 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lumbar interlaminar epidural injection with local anesthetic only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lumbar Interlaminar Epidural Injection with local anesthetic wiht 6 mg of non-particulate Celestone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar Interlaminar Epidural</intervention_name>
    <description>Lumbar interlaminar epidural injections under fluoroscopy&#xD;
Epidural tray and needle&#xD;
Drugs:&#xD;
0.5% Xylocaine and non-particulate Celestone</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar Interlaminar Epidural injection</intervention_name>
    <description>Lumbar interlaminar epidural injections under fluoroscopy&#xD;
Epidural tray and needle&#xD;
Drugs:&#xD;
0.5% Xylocaine and non-particulate Celestone</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of at least 18 years of age&#xD;
&#xD;
          -  Subjects with a history of chronic, function-limiting chronic low back pain of at&#xD;
             least 6 months in duration&#xD;
&#xD;
          -  Subjects who are able to give voluntary, written informed consent to participate in&#xD;
             this investigation&#xD;
&#xD;
          -  Subjects who, in the opinion of the PI, are able to understand this investigation,&#xD;
             co-operate with the investigational procedures, and are willing to return to the&#xD;
             center for all the required post-operative follow-ups&#xD;
&#xD;
          -  Subjects have not had recent surgical procedures within the last 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cauda Equina symptoms and/or compressive radiculopathy&#xD;
&#xD;
          -  Narcotic use of no greater than hydrocodone 100 mg/day, methadone of 60 mg, or&#xD;
             morphine 180 mg, or dose equivalent&#xD;
&#xD;
          -  Uncontrolled major depression or uncontrolled psychiatric disorders&#xD;
&#xD;
          -  Uncontrolled or acute medical illnesses including coagulopathy, renal insufficiency,&#xD;
             chronic liver dysfunction, progressive neurological deficit, urinary sphincter&#xD;
             dysfunction, infection, increased intracranial pressure, pseudotumor cerebri,&#xD;
             intracranial tumors, unstable angina, and severe chronic obstructive pulmonary&#xD;
             disease.&#xD;
&#xD;
          -  Chronic severe conditions that could interfere with the interpretations of the outcome&#xD;
             assessments for pain and bodily function&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Subjects who have participated in a clinical study with an investigational product&#xD;
             within 30 days of enrollment&#xD;
&#xD;
          -  Patients with multiple complaints involving concomitant hip osteoarthritis, due to the&#xD;
             overlap of pain complaints&#xD;
&#xD;
          -  Inability to achieve appropriate positioning and inability to understand informed&#xD;
             consent and protocol&#xD;
&#xD;
          -  History of adverse reaction to local anesthetic or anti-inflammatory drugs and history&#xD;
             of gastrointestinal bleeding or ulcers&#xD;
&#xD;
          -  Previous surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laxmaiah Manchikanti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ambulatory Surgery Center, Paducah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulatory Surgery Center</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2008</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pain Management Center of Paducah</investigator_affiliation>
    <investigator_full_name>Laxmaiah Manchikanti, MD</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>lumbar disc herniation</keyword>
  <keyword>discogenic pain</keyword>
  <keyword>lumbar interlaminar epidural</keyword>
  <keyword>injections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

